Contrast Auto-injectors Gain Momentum in Western Europe?
The use of auto-injectors to ensure controlled and efficient contrast delivery for quick and accurate imaging modality diagnosis is gathering momentum in Western Europe. To exploit the market upswing, auto-injector and imaging modality vendors are exploring various combination options to promote bundled sales.
New analysis from Frost & Sullivan, Western European Contrast Auto-injectors Market, finds that the market earned revenues of $40.4 million in 2013 and estimates this to reach $49.6 million in 2018 at a compound annual growth rate of 4.2%. The study covers computed tomography (CT), magnetic resonance imaging (MRI) and angiography auto-injectors.
“The reduction of medical errors due to the adoption of innovative technologies including auto-injectors, readily available consumables, and preloaded/prefilled syringes with contrast agent/medium is encouraging market activity in Western Europe,” said Frost & Sullivan Healthcare Senior Research Analyst Srikanth Kompalli. “The focus is mainly on developing a cost-effective imaging solution that yields even better precision and facilitates the transfer of diagnostic information within the hospital.”
As such, economical auto-injectors and time-saving examinations with documented hygiene safety in diagnostic imaging procedures are expected to grab the attention of key decision-makers in hospitals and Food and Drug Administration authorities. Scalable informatics-ready solutions, along with CT and MRI auto-injectors that offer radiation and contrast dose management options, will also gain popularity in large private hospitals. They provide a complete injector interface between the scanner, picture archiving and communication system (PACS), and radiology information system (RIS).
However, budget constraints and further reimbursement reductions will negatively impact the market in the next few years. Already, increasing cutbacks in healthcare spending across Western European countries is making the initial investment required for imaging systems unaffordable and, in turn, adversely affecting the contrast auto-injectors market. To add to market woes, the lengthy product lifecycles of CT and MRI injectors is hindering sales while the promotion of combination systems is hampering the growth of modality-based injectors.
“Notwithstanding these challenges, contrast auto-injectors with features like automated workflow and integrated features to work in other imaging modalities are finding acceptance in Western Europe,” noted Kompalli. “Programmable contrast injectors, which help minimise the contrast media being wasted and allow for efficient time management, are also witnessing greater demand.”
Market potential is set to grow with some manufacturers offering extravasation sensors that give a warning if the injector needle is embedded in the tissue instead of inside the vessel, adding to safety. For angiography auto-injectors, new programmed automatic injection devices that allow online hemodynamic monitoring as well as control of injection rate and amount of contrast to be delivered are making headway in the interventional modality space.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance